WO2021112176A1 - Composition d'amélioration de la qualité du sommeil - Google Patents

Composition d'amélioration de la qualité du sommeil Download PDF

Info

Publication number
WO2021112176A1
WO2021112176A1 PCT/JP2020/045036 JP2020045036W WO2021112176A1 WO 2021112176 A1 WO2021112176 A1 WO 2021112176A1 JP 2020045036 W JP2020045036 W JP 2020045036W WO 2021112176 A1 WO2021112176 A1 WO 2021112176A1
Authority
WO
WIPO (PCT)
Prior art keywords
daylily
sleep
oral preparation
fresh leaves
fermented
Prior art date
Application number
PCT/JP2020/045036
Other languages
English (en)
Japanese (ja)
Inventor
哲 渡嘉敷
案理 酒井
竜嗣 竹田
Original Assignee
株式会社クレイ沖縄
哲 渡嘉敷
渡嘉敷 朝子
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社クレイ沖縄, 哲 渡嘉敷, 渡嘉敷 朝子 filed Critical 株式会社クレイ沖縄
Priority to CN202080084089.8A priority Critical patent/CN115023234A/zh
Priority to JP2021562715A priority patent/JPWO2021112176A1/ja
Publication of WO2021112176A1 publication Critical patent/WO2021112176A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Definitions

  • the present invention relates to a composition for improving sleep quality.
  • Patent Document 1 proposes a sleep quality improving agent containing an extract of Ash genus plant or Siberian larix sibir.
  • Akinowasuregusa (Okinawa name: Yamansou, Niibui grass), which is a plant belonging to the genus Daylily of the Liliaceae family, is said to be effective for sleeplessness since the Ryukyu dynasty. It has been eaten as a kind of medicinal food. In modern times, it is also used for beverages such as tea and confectionery, and flowers are beautiful for ornamental purposes and are attracting attention as a representative material of Okinawa.
  • daylily contains a compound that has an effect on sleep improvement
  • daylily contains a compound that has an effect on sleep improvement
  • the compound that has an effect on sleep improvement is efficient.
  • the technology for good inclusion is underdeveloped.
  • Item 1 An oral preparation for improving sleep quality that contains fermented fresh leaf extract of daylily as an active ingredient.
  • Item 2. The oral preparation according to Item 1, wherein the quality of sleep is reduction of drowsiness at the time of waking up, recovery from fatigue at the time of waking up, reduction of sleep onset time, increase of non-REM sleep, or reduction of awakening during sleep.
  • Item 3. The oral preparation according to Item 1 or 2, wherein the water content of the fresh leaves of the daylily is 10% or more.
  • Item 4 The oral preparation according to any one of Items 1 to 3, wherein the fresh leaves of the daylily are obtained from the daylily within 4 months after the flower fall.
  • Item 5 The oral preparation according to any one of Items 1 to 4, wherein the daily intake of the fermented fresh leaf extract of Akinowasuregusa is 100 mg / day to 4000 mg / day in terms of dry solid content.
  • FIG. 1 is a graph showing the results of the OSA sleep questionnaire (factor I: drowsiness when waking up) in Test Example 1.
  • FIG. 2 is a graph showing the results of the OSA sleep questionnaire (factor IV: recovery from fatigue) in Test Example 1.
  • FIG. 3 is a graph showing the results of a sleep electroencephalograph (sleep onset latency, halfway awakening time ratio, non-REM sleep) in Test Example 1.
  • FIG. 4 is a graph showing the results of evaluating the seasonal variation of oxypinnatanin contained in the flowers of the daylily daylily in Test Example 2.
  • FIG. 5 is a graph showing the results of evaluating the seasonal variation of oxypinnatanin contained in the leaves or roots of Daylily chinensis in Test Example 2.
  • Daylily (Hemerocallis fulva var. Semipervirens) is a plant belonging to the genus Daylily of the Liliaceae family. "Akinowasuregusa” is a Japanese name, and in Okinawa Prefecture, it is also called by dialect names such as Kwansou, Kwansou, and Nibuigusa.
  • the production area of the daylily is not particularly limited, but for example, domestic or foreign production can be mentioned, and if it is domestic, for example, Okinawa Prefecture, southern Kyushu, Nansei Islands, etc. can be mentioned, and if it is foreign, for example, Asia such as China and Taiwan can be mentioned.
  • the site from which the daylily extract is extracted is from the whole plant or leaves, stems, buds, roots, and flowers.
  • the site from which the daylily extract is extracted is from the whole plant or leaves, stems, buds, roots, and flowers.
  • the present inventors have newly found that the content of oxypinnatanine in the leaves of daylily is significantly reduced by undergoing the drying process. Therefore, the leaves of the daylily daylily are preferably fresh leaves (undried).
  • a stem and / or a bud of the daylily as the extraction site in combination with the leaf of the daylily. Even when these extraction sites are used, it is preferable to use them in a raw state because the content of oxypinnatanine is significantly reduced by the drying step.
  • the present inventors have found that the content of oxypinnatanine is significantly reduced by flowering from the state of buds of the daylily flower, and the flower of the daylily is extracted. It is also preferable to exclude from.
  • Akinowasuregusa is preferably obtained by fermenting fresh leaves from the viewpoint of significantly improving the quality of sleep.
  • the water content of the fresh leaves (undried matter) of the daylily can be, for example, 10% or more, preferably 15% or more, more preferably 20% or more, still more preferably 25% or more.
  • the above-mentioned water content is preferably the above-mentioned water content at the time of sale if it is a commercially available product of fresh leaves of Akinowasuregusa, and more preferably the above-mentioned water content at the time of being subjected to fermentation treatment.
  • the present inventors have newly found that the content of oxypinnatanine in the fresh leaves of daylily is significantly reduced depending on the harvest time. Specifically, it can be seen that the content of oxypinnatanine in the leaves increases remarkably 3 to 4 months after the flowering period has passed and the content of oxypinnatanin in the leaves decreases sharply 4 months after the flowering. It was issued. Therefore, the fresh leaves of Daylily are preferably harvested within at least 4 months after the fall of flowers, more preferably 1 to 4 months after the fall of flowers, and 2 to 4 months after the fall of flowers. It is more preferable that the daylily is harvested in a month, and it is particularly preferable that the daylily is harvested 3 to 4 months after the flower falls.
  • Fermentation means known to those skilled in the art may be used in the fermentation process for obtaining the fermented product.
  • the fermentation means include aspergillus, lactic acid bacteria, and yeast.
  • yeast for example, yeast can be preferably used.
  • Aspergillus examples include filamentous fungi belonging to the genus Aspergillus.
  • lactic acid bacteria examples include bacteria belonging to the genus Lactobacillus, Lactococcus or Streptococcus.
  • yeast examples include those belonging to the genus Saccharomyces, the genus Schizosaccharomyces, the genus Kluyveromyces, or the genus Pichia.
  • Saccharomyces cerevisiae which is also called yeast, or a subspecies thereof is preferable from the viewpoint of remarkably exerting the effect of the present invention.
  • Fermentation treatment conditions can be appropriately selected by those skilled in the art, for example.
  • the conditions of the fermentation treatment include, for example, a step of mixing the yeast Saccharomyces cerevisiae with at least a part of the fresh leaves of the daylily, and it is preferable to mix it with the juice of the fresh leaves of the daylily.
  • the temperature condition of the fermentation treatment can be, for example, 20 to 50 ° C, preferably 25 to 45 ° C, more preferably 30 to 40 ° C, and even more preferably 35 to 38 ° C.
  • the fermentation treatment time can be, for example, 20 to 70 hours, preferably 25 to 65 hours, and more preferably 30 to 60 hours.
  • a sterilization step may be included as appropriate.
  • the fermentation treatment may include, for example, a step of immersing at least a part of the fresh leaves of the daylily in water. It is possible to add the above-mentioned fermentation means, for example, yeast, to the fresh leaves of the daylily soaked in water, and to carry out the fermentation treatment.
  • the above-mentioned fermentation means for example, yeast
  • the immersion time in the immersion step can be, for example, 10 minutes to 10 hours, preferably 30 minutes to 8 hours, more preferably 40 minutes to 5 hours, and further preferably 1 hour to 3 hours.
  • the dipping step may include a step of boiling water.
  • the fresh leaves of the daylily, which is applied to the fermentation treatment, may be crushed before being subjected to the fermentation treatment.
  • the fresh leaves of the daylily which is applied to the fermentation treatment, may be squeezed before being subjected to the fermentation treatment. Without limitation, it is preferable to apply the juice of fresh leaves of the pressed daylily daylily to the fermentation treatment.
  • the fresh leaves of the daylily applied to the fermentation treatment may be ground or ground before the fresh leaves of the daylily are fermented.
  • the paste of fresh leaves of the daylily ground daylily to the fermentation treatment, the fermentation efficiency is increased, and the paste is suitable for, for example, solid formulation.
  • the fresh leaves of the daylily are heat-treated to inactivate various enzymes contained in the fresh leaves of the daylily before or after the fermentation treatment, preferably after the fermentation treatment. It is preferable to carry out.
  • the temperature condition of the heat treatment can be, for example, 60 to 100 ° C., preferably 70 to 95 ° C., and more preferably 75 to 90 ° C.
  • the time of the heat treatment can be, for example, 10 seconds to 10 minutes, preferably 10 seconds to 5 minutes, and more preferably 10 seconds to 3 minutes.
  • the fresh leaves of the daylily are added to or in place of the heat treatment of the daylily before or after being subjected to the fermentation treatment, preferably after being subjected to the fermentation treatment. It is preferable to carry out a freezing treatment to inactivate various enzymes contained in the fresh leaves.
  • a freezing treatment to inactivate various enzymes contained in the fresh leaves.
  • the temperature condition of the freezing treatment for example, it is preferably -4 ° C or lower, more preferably -10 ° C or lower, further preferably -15 ° C or lower, and more preferably -18 ° C or lower. It is particularly preferable, and most preferably it is -20 ° C or lower.
  • the freezing treatment makes it possible to use the fermented leaf extract of Daylily daylily in frozen foods, frozen desserts, etc., and by inactivating various enzymes contained in the fresh leaf of Daylily daylily, oxypinnatanine It becomes possible to produce foods in which decomposition is suppressed.
  • a fermented extract obtained by subjecting the fresh leaves of Akinowasuregusa to the above-mentioned fermentation treatment may be used, or a commercially available fermented product may be used.
  • the daily intake of the fermented leaf extract of Daylily daylily can be, for example, 100 mg / day to 4000 mg / day, preferably 200 mg / day to 3500 mg / day in terms of dry solid content. Can be a day.
  • the oral preparation of the present invention may have an oxypinnatanine content of, for example, 2 mg / day to 20000 mg / day, preferably 2 mg / day to 10000 mg / day, and more preferably 2 mg / day to 2500 mg / day. Particularly preferably, it can be 2 mg / day to 2000 mg / day.
  • 100 g of the fermented leaf extract of Daylily daylily preferably contains 2 mg or more of oxypinnatanine, for example, 2 mg to 20000 mg, 2 mg to 10000 mg, 2 mg to 2500 mg, 2 mg to 2000 mg, and the like. can do.
  • the oral preparation of the present invention is used for improving the quality of sleep.
  • improvement refers to an improvement in the state of sleep quality, prevention or delay of deterioration of the state of sleep quality.
  • the quality of sleep may be the quality of sleep during the entire sleep period or the quality of sleep during a part of the sleep period.
  • Sleep is preferably sleep in the first cycle, which allows the brain to rest efficiently. There are REM sleep and non-REM sleep in sleep, and REM sleep and non-REM sleep alternate during sleep.
  • the sleep cycle is the period from the end of one REM sleep to the end of the next REM sleep.
  • the first sleep cycle means the first sleep cycle after falling asleep.
  • the sleep quality refers to the observation of one or more, preferably two or more, of the reduction of drowsiness when waking up, the recovery of fatigue when waking up, the decrease in sleep onset time, the increase in non-REM sleep, and the decrease in awakening during sleep. ..
  • Reducing drowsiness when waking up means reducing the feeling of lack of sleep when waking up.
  • Fatigue recovery when waking up means that the feeling of fatigue when waking up is reduced.
  • a decrease in sleep onset time means that the time to fall asleep is shortened.
  • An increase in non-REM sleep means that the ratio of non-REM sleep time to the total sleep time increases.
  • a decrease in awakening means a decrease in the number of times you wake up in the middle of sleep.
  • the oral preparation of the present invention can also be orally administered as a solid preparation such as tablets, capsules, granules, syrups and powders.
  • a solid preparation such as tablets, capsules, granules, syrups and powders.
  • Excipients, lubricants, binders, disintegrants for solid preparations; solvents, solubilizers, suspending agents, tonicity agents, buffers, soothing agents, etc. should be used for liquid preparations. Can be done. If necessary, additives such as preservatives, antioxidants, colorants, and sweeteners can also be used.
  • Excipients include, for example, sugar alcohols such as D-sorbitol, mannitol and xylitol, sugars such as glucose, sucrose, lactose and fructose, crystalline cellulose, carmellose sodium, croscarmellose sodium, calcium hydrogen phosphate and wheat starch. , Rice starch, corn starch, potato starch, dextrin, ⁇ -cyclodextrin, light anhydrous silicic acid, titanium oxide, magnesium aluminometasilicate, talc, kaolin, olive oil and the like.
  • binder examples include cellulose derivatives such as methyl cellulose, ethyl cellulose, hydroxypropyl cellulose and hydroxypropyl methyl cellulose, polyvinylpyrrolidone, polyvinyl alcohol, acrylate-based polymers, gelatin, arabic gum, purulan, pregelatinized starch, canten, tragant, and the like.
  • cellulose derivatives such as methyl cellulose, ethyl cellulose, hydroxypropyl cellulose and hydroxypropyl methyl cellulose
  • polyvinylpyrrolidone polyvinyl alcohol
  • acrylate-based polymers examples include sodium alginate and propylene glycol alginate.
  • the excipient or binder is at least selected from the group consisting of dried moromi vinegar powder, mashed vinegar, dried mashed vinegar powder, mashed lees, and oligosaccharide cyclodextran (CI). It is also possible to use one type.
  • disintegrant examples include starch, low-degree-of-substitution hydroxypropyl cellulose, carboxymethyl cellulose calcium, croscarmellose sodium, hydroxypropyl starch, and partially pregelatinized starch.
  • solvent examples include water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil and the like.
  • lubricant examples include stearic acid, magnesium stearate, calcium stearate, polyoxyl stearate, cetanol, talc, hydrogenated oil, sucrose fatty acid ester, dimethylpolysiloxane, beeswax, and salashimitsuro.
  • solubilizing agent examples include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like.
  • suspending agent / emulsifier examples include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glycerin monostearate; for example, polyvinyl alcohol and polyvinyl.
  • surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glycerin monostearate; for example, polyvinyl alcohol and polyvinyl.
  • Hydrophilic polymers such as pyrrolidone, sodium carboxymethyl cellulose, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose; for example, shelac wax, beeswax, carnauba wax, whale wax, lanolin, liquid lanolin, reduced lanolin, hard lanolin, cyclic lanolin, lanolin.
  • waxes such as wax, candelilla wax, mokuro, montan wax, cellac wax, and rice wax.
  • tonicity agent examples include sodium chloride, glycerin, D-mannitol and the like.
  • the buffer examples include a buffer solution such as phosphate, acetate, carbonate, and citrate.
  • preservatives include paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
  • At least one selected from the group consisting of moromi vinegar, dried powder of moromi vinegar, and mash lees can be used as a substitute component of a preservative.
  • antioxidant examples include sulfites, ascorbic acid and the like.
  • the oral preparation of the present invention is a solid preparation
  • a production method known in the art can be used. For example, a method of crushing and sizing an extruded granulated product which is formed by kneading an oral pharmaceutical composition and passing it through a screen, adding kneading water to the composition, and stirring the mixture by a vertical granulator. After granulation, a method of crushing and sieving using a combil can be mentioned. Further, a method in which the pharmaceutical composition is compressed with a roller compactor, then pulverized with a roll granulator and sieved is mentioned. Further, a method of drying the fluidized bed after stirring and granulating can be mentioned. Further, for example, in the case of producing by direct striking, the composition may be mixed and then directly put into a locking machine to lock.
  • the oral preparation it is also possible to freeze the fermented leaf extract of Akinowasuregusa to make a solid preparation. Further, for example, it is also possible to mix the fermented fresh leaf extract of Akinowasuregusa and the dried fresh leaf powder of Akinowasuregusa and freeze them to form a solid preparation.
  • the oral preparation of the present invention can also be used as a food or drink, and can be provided by being contained in a food or a functional food.
  • Such foods or functional foods include rice; various noodles including buckwheat, udon, harusame, Chinese noodles, instant noodles, cup noodles; soft drinks, carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, sports drinks.
  • Beverages such as: Curry roux, stew, various soups; Cold confectionery such as ice cream, ice sherbet, shaved ice; Candy, cookies, candies, gum, chocolate, tablets, snacks, biscuits, jelly, jam, cream, and other baked goods
  • Confectionery such as; fishery and livestock processed foods such as kamaboko, hampen, ham, sausage; dairy products such as processed milk and fermented milk; Processed foods; seasonings such as sauces, dressings, miso, soy sauce, sauces; soups, stews, salads, prepared foods, sprinkles, pickles; other various forms of health / nutritional supplements / functional foods / foods for specified health use, etc. Is illustrated.
  • supplements containing the present invention may be prepared.
  • composition of the present invention can be contained in food for animals such as pets.
  • Additives are added to food and drink as needed.
  • Such additives include, for example, glucose, fructose, sucrose, maltose, sorbitol, stebioside, rubusoside, corn syrup, lactate, mannitol, dextrin, citric acid, sodium citrate, tartrate, malic acid, succinic acid, Lactic acid, L-ascorbic acid, dl- ⁇ -tocopherol, sodium erythorbicate, glycerin, propylene glycol, glycerin fatty acid ester, polyglycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, arabic gum, carrageenan, casein, gelatin, pectin , Agar, vitamin C, vitamin Bs, vitamin E, nicotinic acid amide, calcium pantothenate, amino acids, calcium salts, surfactants, pigments, fragrances, preservatives and the like.
  • the present invention can be used for foods and drinks for which labeling of improvement / prevention of various symptoms and conditions is permitted.
  • the foods and drinks for which the labeling of improvement / prevention of symptoms and conditions is permitted are foods and drinks having medicinal effects permitted and designated by the national government and public organizations, for example.
  • the blending amount of the composition of the present invention is not particularly limited, and the purpose of application (target disease, type of symptom, etc.), target site, gender and age of the applicator, food and drink, food with functional claims, etc. , Specified health food, quasi-drug, or drug form, administration or ingestion method and frequency of these, preference, etc. are appropriately set.
  • composition of the present invention is not particularly limited in terms of formulation and dosage form.
  • functional foods such as supplements and nutritional drinks, sweets such as gummies, candy, gum, crackers and biscuits, foods such as ice cream, jelly, yokanpan, bread, steamed tea, curry, milk drinks, soft drinks, etc.
  • Beverages such as soups, dressings, and seasonings such as ponzu vinegar are exemplified as food and drink compositions that can be eaten and drink.
  • composition of the present invention is preferably taken as a functional food from the viewpoint of the effect of the present invention of improving the quality of sleep, and among the functional foods, a food with a functional claim, a food with a nutritional function, and a nutrition. Supplements and foods for specified health use can be mentioned, but foods with functional claims are preferable because their uses can be clearly labeled.
  • composition of the present invention is not particularly limited as long as there is a need to improve the quality of sleep, but is 15 years old, who tends to have a short sleep time due to the need for study and work. It may be over 20 years old, over 30 years old, or over 30 years old. It may be a middle-aged person (around 45 years old or older and less than 55 years old) or an elderly person (55 years old or older) who is likely to feel a change in the body due to a change in hormonal balance or the like.
  • the pH of the composition of the present invention is appropriately set according to the type and content of other compounding ingredients, the form of the preparation, the method of use, etc., and is not limited as long as it is within a physiologically or pharmaceutically acceptable range.
  • the pH can be 2-9.
  • the pH of the composition of the present invention is preferably 2 to 9.5, more preferably 3 to 9, still more preferably 4 to 8.5, and even more preferably.
  • An oral preparation for improving sleep quality that contains fermented fresh leaf extract of daylily as an active ingredient.
  • the above-mentioned oral preparation whose sleep quality is reduction of drowsiness when waking up, recovery from fatigue when waking up, reduction of sleep onset time, increase of non-REM sleep, or reduction of awakening during sleep.
  • the above-mentioned oral preparation whose sleep quality is a decrease in sleep onset time, an increase in non-REM sleep, and / or a decrease in awakening.
  • the above-mentioned oral preparation in which the water content of the fresh leaves of the daylily Akinowasu is 10% or more.
  • the above-mentioned oral preparation in which the treatment for inactivating the enzyme contained in the fresh leaves of the daylily is heat treatment or freezing treatment.
  • the above-mentioned oral preparation in which the daily intake of the fermented leaf extract of Akinowasuregusa is 100 mg / day to 4000 mg / day in terms of dry solid content.
  • the above-mentioned oral preparation having an oxypinnatanine content of 2 mg to 20000 mg in 100 g of the fermented fresh leaf extract of the daylily daylily.
  • the quality of sleep is a decrease in sleep onset time, an increase in non-REM sleep, and / or a decrease in awakening.
  • yeast Saccharomyces cerevisiae or a subspecies thereof.
  • the above-mentioned use which is a treatment for inactivating the enzyme contained in the fresh leaves of the daylily, before or after being subjected to the fermentation treatment.
  • the above-mentioned use in which the treatment for inactivating the enzyme contained in the fresh leaves of the daylily is heat treatment or freezing treatment.
  • the above-mentioned use in which the daily intake of the fermented leaf extract of the daylily Akinowas is 100 mg / day to 4000 mg / day in terms of dry solid content.
  • Fermented fresh leaf extract of daylily which is used to improve sleep quality.
  • the above-mentioned extract whose sleep quality is reduction of drowsiness when waking up, recovery from fatigue when waking up, reduction of sleep onset time, increase of non-REM sleep, or reduction of awakening halfway.
  • the above extract wherein the quality of sleep is a decrease in sleep onset time, an increase in non-REM sleep, and / or a decrease in awakening.
  • the above extract having a water content of 10% or more in the fresh leaves of the daylily.
  • the above extract which has been treated to inactivate the enzyme contained in the fresh leaves of the daylily, before or after being subjected to the fermentation treatment.
  • the above extract in which the treatment for inactivating the enzyme contained in the fresh leaves of the daylily is heat treatment or freezing treatment.
  • the above extract, the temperature condition of the heat treatment is 60 to 100 ° C.
  • the above extract, the time condition of the heat treatment is 10 seconds to 10 minutes.
  • the above extract, the temperature condition of the freezing treatment is -4 ° C or less.
  • the above extract, the temperature condition of the freezing treatment is -20 ° C or less.
  • the above-mentioned extract in which the daily intake of the fermented fresh leaf extract of the daylily is 100 mg / day to 4000 mg / day in terms of dry solid content.
  • the above-mentioned extract in which the content of oxypinnatanine in 100 g of the fermented fresh leaf extract of the daylily daylily is 2 mg to 20000 mg.
  • a method for improving sleep quality including ingesting a fermented fresh leaf extract of Akinowasuregusa as an active ingredient.
  • the quality of sleep is reduction of drowsiness when waking up, recovery from fatigue when waking up, reduction of sleep onset time, increase of non-REM sleep, or reduction of awakening halfway.
  • the quality of sleep is a decrease in sleep onset time, an increase in non-REM sleep, and / or a decrease in awakening.
  • yeast Saccharomyces cerevisiae or a subspecies thereof.
  • the above method which is a treatment for inactivating the enzyme contained in the fresh leaves of the daylily, before or after being subjected to the fermentation treatment.
  • 1 kg of fresh leaves of daylily was cut into a length of about 6 cm, crushed, and then ground to form a paste.
  • Yeast Sacharomyces cerevisiae
  • fermentation treatment was carried out at 35 ° C. to 38 ° C. for about 3 hours.
  • the fermented product was heated to 90 ° C. to inactivate the enzyme and then cooled to obtain a fermented leaf extract of Akinowasuregusa.
  • the fermented fresh leaf extract of daylily was frozen under the condition of -18 ° C or lower in order to suppress the decomposition of oxypinnatanin.
  • the present inventors have found that the amount of oxypinnatanin contained in the fresh leaves of daylily is decomposed and reduced due to the presence of sugars, and the fresh leaves of daylily are fermented to significantly contain oxypinnatanin. I was able to obtain an extract to be used.
  • the subjects were healthy men and women between the ages of 20 and 65 who were mainly working at desk work and were not suffering from illnesses that were aware of mild sleep problems such as tiredness, poor sleep, and light sleep. ..
  • Test method The study was conducted in a randomized, double-blind, placebo-controlled, parallel-group study.
  • screening test 40 subjects were visited to the hospital, and PSQI sleep questionnaire, blood test, urinalysis, and interview were performed, and 32 subjects who met the selection criteria of this study and did not meet the exclusion criteria were selected.
  • pre-ingestion test the selected subjects filled out a one-week OSA sleep questionnaire at the time of waking up and wore a sleep electroencephalograph (ZA-1, Pro Assist) on the day before the working day to measure sleep electroencephalogram. After the completion of the pre-ingestion test, the assigned test food was ingested 4 tablets a day for 2 weeks.
  • ZA-1 sleep electroencephalograph
  • the OSA sleep questionnaire was filled out every day at the time of waking up, and a diary describing the physical condition was kept every day.
  • a sleep electroencephalograph was attached on the day before the working day of the second week of ingestion to measure the sleep electroencephalogram as in the case of the pre-intake examination.
  • the patient was returned to the hospital to perform a blood test and a urine test, as well as a PSQI sleep questionnaire and a post-intake test by interview.
  • test beverages were randomly assigned by the person in charge of allocation who was not involved in the implementation of this study by the substitution block allocation method using age, gender, and PSQI as stratification factors. 16 people were assigned to each of the test products or the placebo food group, and ingestion was started. The intake period was 2 weeks. A sleep quality survey was conducted using the OSA sleep questionnaire during the ingestion period, and sleep electroencephalograms were measured in the second week of ingestion. The study was completed in all subjects and no one dropped out. However, the sleep electroencephalograph data could not be obtained for one person in the placebo intake group, so it was regarded as deficient.
  • the OSA sleep questionnaire is a psychological scale that evaluates sleep introspection when waking up, and is a questionnaire that determines the quality of sleep used in sleep outpatient clinics.
  • the sleep questionnaire is divided into five factor components.
  • the Akinowasregusa intake group was compared with the placebo intake group in terms of the ratio of the awakening time, the latency of falling asleep 2 weeks after the intake and the amount of change from before the intake. It decreased significantly. In addition, the rate of non-REM sleep was significantly increased in the daylily intake group compared with placebo.
  • the flowers, leaves, and roots of the daylily were collected in a raw state, extracted with methanol at room temperature for a whole day and night without drying, and then concentrated under reduced pressure to prepare an extract.
  • Figure 4 shows the results of evaluating the seasonal variation of oxypinnatanine associated with flowering. The results of evaluating the fluctuation of oxypinnatanin before the flowering period in the leaves and roots are shown in FIG.
  • Oxypinnatanin is relatively stable when dissolved in water and at pH 1.2 to pH 6.8, suggesting that oxypinnatanin may be accumulated at high density in the early stages of plant organs and consumed during the growth process. Was done. Therefore, although not limited, it was confirmed that it is preferable to collect the fresh leaves of the daylily daylily within one month after the flower fall and prepare it as an extract without drying. In this case as well, it is more preferable to carry out the fermentation treatment using yeast, for example, yeast, in order to prevent the oxypinnatanine contained in the fresh leaves of the daylily from being decomposed and reduced due to the presence of sugars.
  • yeast for example, yeast
  • the activated partial thromboplastin time and the prothrombin time in the male test substance group were significantly prolonged as compared with the control group.
  • this change was not observed in females, and no bleeding tendency was observed in the subcutaneous findings at autopsy in the male test substance group, and blood biochemical and histopathological changes suggesting liver abnormalities were observed.
  • the significant thromboplastin time and prothrombin time of the activated partial thromboplastin observed in the male test substance group are significant. Prolongation was not considered to be a direct toxic reaction due to administration of the test substance.
  • Myocardial degeneration / fibrosis was observed in one male in the test substance-administered group. Although this change was a change in the test substance-administered group, it was a very slight change and no similar change was observed in other animals in the same group. Since there was no increase in AST) value, degeneration / fibrosis of the myocardium of this animal was considered to be an accidental finding.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une préparation orale qui peut exercer efficacement un effet d'amélioration de la qualité du sommeil.　Une préparation orale destinée à améliorer la qualité du sommeil est préparée et contient un extrait de fermentation de feuilles fraîches d'hémérocalle orange (Hemerocallis fulva L. var. sempervirens) en tant que principe actif.
PCT/JP2020/045036 2019-12-03 2020-12-03 Composition d'amélioration de la qualité du sommeil WO2021112176A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202080084089.8A CN115023234A (zh) 2019-12-03 2020-12-03 睡眠质量提升用组合物
JP2021562715A JPWO2021112176A1 (fr) 2019-12-03 2020-12-03

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019-218971 2019-12-03
JP2019218971 2019-12-03

Publications (1)

Publication Number Publication Date
WO2021112176A1 true WO2021112176A1 (fr) 2021-06-10

Family

ID=76222426

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/045036 WO2021112176A1 (fr) 2019-12-03 2020-12-03 Composition d'amélioration de la qualité du sommeil

Country Status (4)

Country Link
JP (1) JPWO2021112176A1 (fr)
CN (1) CN115023234A (fr)
TW (1) TW202133873A (fr)
WO (1) WO2021112176A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006062998A (ja) * 2004-08-25 2006-03-09 Ryukyu Bio Resource Kaihatsu:Kk 睡眠改善剤
WO2008146883A1 (fr) * 2007-05-29 2008-12-04 Osaka Bioscience Institute Agent d'amélioration du sommeil
JP2011195482A (ja) * 2010-03-18 2011-10-06 Doshisha 睡眠改善剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006062998A (ja) * 2004-08-25 2006-03-09 Ryukyu Bio Resource Kaihatsu:Kk 睡眠改善剤
WO2008146883A1 (fr) * 2007-05-29 2008-12-04 Osaka Bioscience Institute Agent d'amélioration du sommeil
JP2011195482A (ja) * 2010-03-18 2011-10-06 Doshisha 睡眠改善剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OGAWA, YUKO, KONISHI, TENJI: "P-50 Physiological role of Oxypinnatanine", THE 51ST SYMPOSIUM ON THE CHEMISTRY OF NATURAL PRODUCTS, SYMPOSIUM PAPERS, ''2. FLUCTUATIONS IN OPT CONTENT IN HEMEROCALLIS PLANTS, vol. 51, 2009, pages 617 - 622, XP055832092, ISSN: 2443-1856 *

Also Published As

Publication number Publication date
CN115023234A (zh) 2022-09-06
JPWO2021112176A1 (fr) 2021-06-10
TW202133873A (zh) 2021-09-16

Similar Documents

Publication Publication Date Title
WO2011037099A1 (fr) Composition comprenant un extrait de curcuma longa conjointement avec un extrait de curcuma zedoaria
KR101860165B1 (ko) 식품, 약물, 화장품, 식이 보충제 및 생물제제의 성분으로서의 커피 추출물
JPH09176019A (ja) 糖質分解消化酵素阻害剤並びにこれを配合した医薬品および飲食品
KR20150005430A (ko) 월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물
JP2016199491A (ja) 気分状態改善剤
KR20060009391A (ko) 미나리과 식물 유래의 추출물 및 그 제조 방법
US20190336460A1 (en) Composition comprising formic acid or pharmaceutically acceptable salt thereof as active ingredient for preventing or treating obesity or metabolic syndromes caused by obesity
WO2021112176A1 (fr) Composition d'amélioration de la qualité du sommeil
KR101910013B1 (ko) 한약재 추출물（ｓｏｃｇ）을 함유하는 통증의 개선, 예방 또는 치료용 조성물
KR101626642B1 (ko) 당뇨병 개선 효과능이 있는 탱자 발효 조성물
KR102456356B1 (ko) 락토바실러스 혼합균주를 유효성분으로 포함하는, 월경전 증후군 완화용 조성물
KR100481114B1 (ko) 바나바, 호로파 및 여주 추출물의 발효물을 유효성분으로함유하는 혈당강하용 약학적 조성물
JP2005304355A (ja) そば芽抽出エキスを含有する食品
KR20160026595A (ko) 율무, 표고버섯, 탱자 및 옥수수수염의 혼합물을 포함하는 비만 및 비만관련 질환의 예방 또는 개선용 조성물
JP4371431B2 (ja) 抗アレルギー性組成物
JP2007031297A (ja) 美白用組成物
US20090318552A1 (en) Pharmaceutical composition comprising shikonin derivatives from lithospermum erythrorhizo dor treating or preventing diabetes mellitus and the use thereof
KR102122408B1 (ko) 자감초 추출물을 유효성분으로 포함하는 남성갱년기 증후군의 예방, 개선 또는 치료용 조성물
JP4669077B1 (ja) アスパラガス擬葉を有効成分とする自律神経調整剤
KR20210085011A (ko) 숙잠 및 효모 추출물을 유효성분으로 함유하는 숙취 해소용 조성물
JP4464082B2 (ja) ヨモギを有効成分として含有する筋肉細胞糖輸送促進組成物
KR101811210B1 (ko) 마가목 열매 추출물을 유효성분으로 하는 당뇨 질환 치료, 개선 또는 예방용 조성물
EP3701953A1 (fr) Composition pour prévenir ou soulager la stéatose hépatique non alcoolique
KR102302047B1 (ko) 엉겅퀴, 민들레, 배, 아로니아 및 꿀로 이루어진 혼합물을 함유하는 간보호 또는 숙취해소용 조성물
KR101719015B1 (ko) 프루네틴을 유효성분으로 함유하는 비만 또는 대사성 질환의 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20895662

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021562715

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20895662

Country of ref document: EP

Kind code of ref document: A1